DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Wu YL, Zhang L, Kim DW. et al.
Phase Ib/II study of Capmatinib (INC280) plus Gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer.
J Clin Oncol 2018;
36 (31) 3101-3109
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.